Track Record

Track record as reliable nebuliser manufacturer

Since 2010 six inhaled medicinal products which are administered via eFlow® Technology nebulisers were approved by regulatory authorities whether in the US, Europe or Canada. PARI contributed to such filings with its expertise in medical device regulatory affairs. Following PARI’s tradition, eFlow Technology nebulisers are manufactured according to the highest quality standards. Frequent and recurrent quality system audits by our pharma partners confirm this year after year.

Commercial products:

  • Cayston® (Gilead Sciences Inc., administered via the Altera® nebuliser, approved in the US, EU and Canada)
  • ColiFin®/Colfinair® (PARI Pharma GmbH, administered via an eFlow®rapid nebuliser handset, approved in the EU)
  • QUINSAIR™ (Horizon, administered via the Zirela® nebuliser, approved in the EU and Canada)
  • Vantobra® (PARI Pharma GmbH, administered via the Tolero® nebuliser handset, approved in the EU)
  • Lonhala® (glycopyrrolate) Inhalation Solution (Sunovion Pharmaceuticals Inc., administered via the Magnair® nebuliser, approved in the US)
  • ARIKAYCE® (Insmed Incorporated, administered via the Lamira® nebuliser system, approved in the US and EU)

PARI´s track record drug products approved with an eFlow Technology nebulizer in the US, EU and Canada (please note the approval for each drug)

Lamira® for ARIKAYCE®

The Lamira Nebuliser System is specifically optimised for the administration of Insmed´s ARIKAYCE. Insmed is a global biopharmaceutical company headquartered in the USA.

ARIKAYCE (amikacin liposome inhalation suspension) was approved in the USA in 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is the only FDA-approved treatment for this patient population.

This was followed by the approval of ARIKAYCE Liposomal 590 mg Nebuliser Dispersion in the EU in October 2020. It´s the first inhaled liposomal dispersion approved by the European Commission and the first and only therapy in the European Union indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis.

ARIKAYCE has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases. For more information including boxed warning please visit

Further information:

News release FDA approval

News release European Commission approval

LONHALA® MAGNAIR® (glycopyrrolate) Inhalation Solution

LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S. and the first use of the MAGNAIR, which is based on the closed eFlow® Technology nebuliser, developed by PARI Pharma GmbH, to treat COPD. This technology is a virtually silent, portable, closed system nebuliser that is designed to deliver the drug in two to three minutes and allows people to breathe normally while using the device.

Further information:

Featured Videos on LONHALA MAGNAIR


Get a detailed look at the device features of LONHALA MAGNAIR.

Evolution of the nebuliser

Learn about the evolution of nebuliser technology leading up to the MAGNAIR Nebuliser System.


Watch excerpts from an instructional video on how to set-up, administer, and clean LONHALA MAGNAIR which is included in the US approved prescription packaging.

Zirela® for QUINSAIR

San Diego based Mpex Pharmaceuticals Inc. initiated the development of inhaled Levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Raptor Pharmaceuticals Inc. valued QUINSAIR with an upfront payment of $68 million, up to $34 million Raptor shares as well as contingent payments of up to $350 million. Inhaled Levofloxacin is sold under the brand name QUINSAIR in Europe and Canada since 2016 and is administered via an eFlow® Technology nebuliser called Zirela.

Further information:

Tolero® for Vantobra®

Vantobra (Tobramycin 170 mg) is a development and proprietary drug product of PARI Pharma. It is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF). Vantobra is administered via an eFlow® nebuliser handset called Tolero and distributed in some EU countries by PARI owned subsidiaries or selected distribution partners.

Further information: [German page] [English page]

ColiFin® / Colfinair®

ColiFin / Colfinair (Colistimethate sodium for nebulisation) is a product of PARI Pharma. It may be used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults and children with cystic fibrosis. The medicinal product is administered via an eFlow®rapid nebuliser handset. ColiFin / Colfinair provide the patient with the saline solution for reconstitution and a new nebuliser handset with each package. This specific drug and device concept is marketed in several countries in the EU and highly accepted providing a unique selling proposition in the treatment of chronic pulmonary infections.

Further information: [German page] [Austrian page]

ARIKAYCE is a registered trademark of Insmed Incorporated
Cayston® is a registered trademark of Gilead Sciences Inc.
Lonhala® is a registered trademark of Sunovion Pharmaceuticals Inc.
SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
QUINSAIR is a trademark of Horizon
eFlow®, eBase®, eLete®, eTrack®, ePort®, eRapid®, Altera®, Zirela®, Tolero®, Magnair®, Lamira®, Vantobra®, ColiFin®, Colfinair® and Vibrent® are registered trademarks of PARI Pharma GmbH

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!


I have acknowledged the information regarding data processing.